Rosuvastatin vs Simvastatin: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Rosuvastatin inhibits HMG-CoA reductase to block the mevalonate pathway, depleting CoQ10 alongside cholesterol. Its hydrophilic structure limits penetration into non-hepatic tissues, potentially reducing muscle-specific CoQ10 depletion compared to lipophilic statins. CTD documents 126 gene interactions — one-third of simvastatin's count — reflecting a more selective hepatic targeting. The same mevalonate blockade impairs vitamin D hydroxylation and reduces vitamin K2-dependent protein carboxylation.
Rosuvastatin has 20% bioavailability with a 19-hour half-life and minimal CYP metabolism — cleared primarily through OATP1B1 hepatic uptake and biliary excretion, eliminating most CYP-mediated drug interactions.
- ✓Most potent statin per milligram — 5 mg rosuvastatin matches approximately 20 mg simvastatin for LDL reduction
- ✓Hydrophilic structure limits muscle tissue penetration, potentially reducing myopathy from CoQ10 depletion
- ✓Minimal CYP metabolism means far fewer drug interactions than simvastatin
- ✓Only 126 CTD gene interactions versus simvastatin's 375 — a more selective molecular profile
- ✗PharmGKB Level 1A evidence shows OATP1B1 transporter variants dramatically alter blood levels in some patients
- ✗Higher cost than generic simvastatin for lifelong therapy
- ✗Less long-term outcomes data compared to simvastatin's decades of landmark trials (4S, HPS)
- ✗Same three-nutrient depletion burden through identical mevalonate pathway blockade
Patients on multiple medications needing minimal drug interactions, those who experienced muscle pain on lipophilic statins, or anyone needing maximum LDL reduction at the lowest dose.
Simvastatin is a lipophilic prodrug converted to its active hydroxy acid in the liver. CTD documents 375 gene interactions — 3x rosuvastatin's count — spanning not just mevalonate genes but inflammatory, apoptotic, and immune signaling pathways. Its lipophilic structure penetrates muscle tissue more readily than rosuvastatin, potentially depleting CoQ10 directly in myocytes and contributing to the higher myopathy rates that prompted the FDA to restrict its maximum dose.
Simvastatin has only 5% oral bioavailability with a 2.5-hour half-life, requiring strict evening dosing to align peak HMG-CoA reductase inhibition with overnight cholesterol synthesis.
- ✓One of the cheapest generic statins — maximizing budget for CoQ10 and vitamin D supplementation
- ✓Landmark trial pedigree: 4S trial (4,444 patients) and HPS (20,536 patients) proved mortality benefit
- ✓Short half-life means faster CoQ10 recovery after discontinuation compared to rosuvastatin
- ✓Decades of real-world experience informing supplement timing protocols
- ✗375 CTD gene interactions — 3x rosuvastatin — indicate much broader systemic metabolic disruption
- ✗FDA restricted 80 mg dose due to elevated myopathy and rhabdomyolysis risk from CoQ10 muscle depletion
- ✗Evening-only dosing requirement due to short 2.5-hour half-life limits scheduling flexibility
- ✗Lipophilic structure penetrates muscle tissue, intensifying CoQ10 depletion where it matters most
Cost-sensitive patients with moderate cardiovascular risk who can take evening doses and don't need maximum LDL reduction.
Feature Comparison
| Feature | Rosuvastatin | Simvastatin |
|---|---|---|
| Drug Class | HMG-CoA reductase inhibitor (hydrophilic) | HMG-CoA reductase inhibitor (lipophilic prodrug) |
| Nutrients Depleted | 3 — CoQ10, vitamin D, vitamin K2 | 3 — CoQ10, vitamin D, vitamin K2 |
| CTD Gene Interactions | 126 documented | 375 documented (3x more) |
| Bioavailability | 20% | 5% |
| Half-Life | 19 hours | 2.5 hours |
| Metabolism | Minimal CYP; OATP1B1 hepatic | CYP3A4 (hepatic oxidation) |
| LDL Potency (per mg) | Highest of any statin | Moderate (80 mg restricted) |
| Muscle Tissue Penetration | Limited (hydrophilic) | High (lipophilic) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both statins deplete the same three nutrients through identical mevalonate pathway blockade, but rosuvastatin's hydrophilic design and narrower gene interaction profile (126 vs 375 in CTD) make it the pharmacologically cleaner choice. Simvastatin's lipophilic structure penetrates muscle tissue where CoQ10 depletion matters most, contributing to the myopathy rates that prompted the FDA's 80 mg dose restriction. Rosuvastatin's minimal CYP metabolism eliminates the drug interaction headaches simvastatin creates through CYP3A4. Simvastatin's advantages are cost and landmark trial pedigree (4S, HPS proving mortality benefit). For patients who can afford it, rosuvastatin offers greater potency per milligram, fewer interactions, and potentially less muscle-specific CoQ10 depletion. Either way, CoQ10 100 mg ubiquinol, vitamin D3 2,000–5,000 IU, and vitamin K2 100–200 mcg MK-7 address the complete three-nutrient depletion.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 126 gene interactions for rosuvastatin; 375 for simvastatin including inflammatory and apoptotic pathway genes
- [2]Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389 — landmark simvastatin mortality trial (4,444 patients)
- [3]FAERS (FDA Adverse Event Reporting System): safety reports for both statins across cardiovascular indications
- [4]PharmGKB pharmacogenomics database: SLCO1B1 Level 1A evidence for statin myopathy risk; OATP1B1 variant annotations for rosuvastatin
- [5]PubMed PMID 22085343 — FDA Drug Safety Communication: new dose restrictions for simvastatin (Zocor) 80 mg. 2011
Check your medications
Check Free →